Rebamipide: A Novel Agent in the Treatment of Recurrent Aphthous Ulcer and Behcet's Syndrome.

Indian J Dermatol

Department of Dermatology and Venereology, Srinivas Institute of Medical Sciences and Research Centre, Mukka, Surathkal, Mangalore, Karnataka, India.

Published: September 2013

Rebamipide is an amino acid analog of 2 (1H)-quinolinone. It is being introduced and used since 1980 for the treatment of peptic ulcer. Its therapeutic use in recurrent aphthous ulcer was not known. It acts by the decrease in oxygen radicals, increase in blood flow and production of protective prostaglandins in ulcer mucosa, which accelerates the process of healing. In this article, we focus on the pharmacodynamics, pharmacokinetics, side-effects and other therapeutic uses of Rebamipide. It will be a new and effective drug in the dermatologists' drug armamentarium for the treatment of aphthous ulcers and related diseases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778773PMC
http://dx.doi.org/10.4103/0019-5154.117298DOI Listing

Publication Analysis

Top Keywords

recurrent aphthous
8
aphthous ulcer
8
rebamipide novel
4
novel agent
4
agent treatment
4
treatment recurrent
4
ulcer
4
ulcer behcet's
4
behcet's syndrome
4
syndrome rebamipide
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!